Dordaviprone and Relugolix: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Relugolix
Dordaviprone
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Both of these medicines can affect your heart's electrical rhythm. Relugolix (Orgovyx) lowers testosterone to treat prostate cancer, and that hormone drop can slightly stretch out a part of the heartbeat called the QT interval. Dordaviprone can do the same thing. When you take them together, those effects can add up and, in rare cases, lead to an irregular heartbeat.
The good news is this is a theoretical concern that your care team knows how to watch for. They may check your heart with an ECG and keep an eye on blood minerals like potassium and magnesium. Please don't stop either medicine on your own. Just talk with your doctor or pharmacist so they can manage this safely.
Additive QT prolongation risk. Both agents can prolong the QT interval; androgen deprivation from relugolix (a GnRH antagonist) plus dordaviprone's QT effect produce additive PD risk of QTc prolongation and torsades de pointes. Neither is a prodrug relevant here; this is a pharmacodynamic, not metabolic, interaction.
- Evidence: theoretical; severity: major; onset unspecified.
- Higher-risk patients: congenital long QT, CHF, electrolyte disturbances.
- Management: avoid concomitant use when possible. If required, correct and maintain normal K+ and Mg2+, avoid other electrolyte-depleting drugs, and obtain periodic ECG and electrolyte monitoring. Weigh ADT benefit against risk.
What happens
Increased risk of QT interval prolongation
Interaction Deep Dive
When relugolix is given together with medications that prolong the QT interval, the effects on the QT interval are additive. The androgen deprivation produced by GnRH agonists and antagonists can itself lengthen the QT interval. In patients who have congenital long QT syndrome, congestive heart failure, or recurrent electrolyte disturbances, as well as those receiving drugs recognized to prolong the QT interval, weigh whether the benefits of androgen deprivation therapy such as relugolix outweigh the possible risks1. Where feasible, do not use relugolix at the same time as QT prolonging agents. Should coadministration be necessary, steer clear of drugs that produce electrolyte abnormalities (that is, hypokalemia or hypomagnesemia) 2, correct any electrolyte abnormalities, and consider periodic monitoring of electrolytes and ECGs 1.
Why it happens (mechanism)
Additive QT interval prolongation
How to manage this interaction
This can usually be managed with monitoring. Keep taking both medicines exactly as prescribed unless your care team tells you otherwise.
- Your team may weigh the benefits of your therapy against your personal heart risk, especially if you have a history of long QT, heart failure, or electrolyte problems.
- Where possible, they may avoid combining QT-prolonging drugs; if both are needed, they may check your ECG and blood electrolytes (potassium, magnesium) periodically and correct any imbalances.
- Tell your pharmacist or doctor about all your medicines, and report fainting, dizziness, or a racing or irregular heartbeat right away.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
1 report — tap to read
a) A study assessed male patients undergoing androgen deprivation therapy (ADT) using individual case safety reports drawn from VigiBase, the international pharmacovigilance database. It identified 184 reports of acquired long-QT syndrome (aLQTS) and/or torsades de pointes (TdP; 11% of which were fatal), along with 99 reports of sudden death linked to ADT. The majority of the aLQTS/TdP cases (62%) and sudden death cases (88%) related to ADT arose without concurrent use of other agents recognized to elevate TdP risk; nevertheless, use of 1 drug and of 2 or more drugs carrying conditional, possible, or known TdP risk was documented in a portion of aLQTS/TdP events (23% or 43%) and sudden death events (18% and 22%). The agents regarded as ADTs included abiraterone, gonadotropin-releasing hormone agonists and antagonists, nonsteroidal androgen receptor inhibitors indicated for prostate cancer, and 5-alpha-reductase inhibitors indicated for androgenic alopecia and prostatism. Among the 10 ADTs examined, 7 showed a disproportional association (reporting odds ratio, 1.4 to 4.7) with aLQTS, TdP, or sudden death, namely leuprorelin, goserelin, triptorelin, degarelix, bicalutamide, finasteride, and dutasteride. The patients had a median age of roughly 76 years, and the median time to onset was 170 days (range, 7 to 4884 days) for aLQTS/TdP events and 92 days (range, 0.25 to 4984 days) for sudden death events. The patients were primarily receiving ADT to manage prostate cancer, with some treated for prostatism and androgenic alopecia. Most patients were taking ADT as monotherapy (83%); 17% were on ADT combination therapy 3.
Common questions
Can I take Dordaviprone and Relugolix together?
Taking relugolix and dordaviprone together can add up to prolong the QT interval, so your care team may monitor your heart rhythm and electrolytes. Keep taking both as prescribed and report any fainting or palpitations. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Dordaviprone and Relugolix interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Dordaviprone and Relugolix interaction managed?
This can usually be managed with monitoring. Keep taking both medicines exactly as prescribed unless your care team tells you otherwise. Your team may weigh the benefits of your therapy against your personal heart risk, especially if you have a history of long QT, heart failure, or electrolyte problems. Where possible, they may avoid combining QT-prolonging drugs; if both are needed, they may chec… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Dordaviprone or Relugolix need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (3)
- Product Information: ORGOVYX oral tablets, relugolix oral tablets. Sumitomo Pharma America, Inc (per FDA), Marlborough, MA, 2025. DailyMed
- Lyon AR, Lopez-Fernandez T, Couch LS, et al: 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 2022; 43(41):4229-4361.
- Salem JE, Yang T, Moslehi JJ, et al: Androgenic effects on ventricular repolarization: a translational study from the international pharmacovigilance database to iPSC-cardiomyocytes. Circulation 2019; 140(13):1070-1080. PubMed
Keep reading about Relugolix
Keep reading about Dordaviprone
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist